Literature DB >> 17220242

Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.

Tracy C Delozier1, Grace E Kissling, Sherry J Coulter, Diana Dai, Julie F Foley, J Alyce Bradbury, Elizabeth Murphy, Charles Steenbergen, Darryl C Zeldin, Joyce A Goldstein.   

Abstract

The cytochrome P450 (P450) enzymes CYP2C8, CYP2C9, and CYP2J2 metabolize arachidonic acid to epoxyeicosatrienoic acids, which are known to be vital in regulation of vascular tone and cardiovascular homeostasis. Because there is limited information regarding the relative expression of these P450 enzymes in cardiovascular tissues, this study examined the expression of CYP2C8, CYP2C9, and CYP2J2 mRNA and protein in human heart, aorta, and coronary artery samples by real-time polymerase chain reaction, immunoblotting, and immunohistochemistry. CYP2J2 and CYP2C9 mRNA levels were highly variable in human hearts, whereas CYP2C8 mRNA was present in lower abundance. CYP2J2 mRNA was approximately 10(3) times higher than CYP2C9 or CYP2C8 in human heart. However, CYP2C9 mRNA was more abundant than CYP2J2 or CYP2C8 in one ischemic heart. In human aorta, mean CYP2C9 mRNA levels were approximately 50 times higher than that of CYP2J2 and 5-fold higher than that of CYP2C8. In human coronary artery, mean values for CYP2C9 mRNA were approximately 2-fold higher than that of CYP2J2 mRNA and 6-fold higher than that of CYP2C8 mRNA. Immunoblotting results show relatively high levels of CYP2J2 and CYP2C8 protein in human hearts, which was confirmed by immunohistochemistry. CYP2C9 protein was also detected at high levels in one ischemic heart by immunoblotting. CYP2C9 was present at higher levels than CYPJ2 in aorta and coronary artery, whereas CYP2C8 protein was below the limits of detection. The expression of CYP2J2 and CYP2C8 in human heart, and CYPC9 and CYP2J2 in aorta and coronary artery is consistent with a physiological role for these enzymes in these tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220242      PMCID: PMC2747652          DOI: 10.1124/dmd.106.012823

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

Review 1.  Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone.

Authors:  W B Campbell; D R Harder
Journal:  Circ Res       Date:  1999-03-05       Impact factor: 17.367

2.  Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction.

Authors:  Arwen L Hunter; Ni Bai; Ismail Laher; David J Granville
Journal:  Vascul Pharmacol       Date:  2005-09-08       Impact factor: 5.773

3.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Authors:  K Node; Y Huo; X Ruan; B Yang; M Spiecker; K Ley; D C Zeldin; J K Liao
Journal:  Science       Date:  1999-08-20       Impact factor: 47.728

4.  Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis.

Authors:  U Ruth Michaelis; Beate Fisslthaler; Eduardo Barbosa-Sicard; John R Falck; Ingrid Fleming; Rudi Busse
Journal:  J Cell Sci       Date:  2005-11-15       Impact factor: 5.285

5.  Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.

Authors:  Brandon T Larsen; Hiroto Miura; Ossama A Hatoum; William B Campbell; Bruce D Hammock; Darryl C Zeldin; John R Falck; David D Gutterman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-10-28       Impact factor: 4.733

Review 6.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.

Authors:  Martin Spiecker; James K Liao
Journal:  Arch Biochem Biophys       Date:  2005-01-15       Impact factor: 4.013

7.  Cytochrome P450 2C is an EDHF synthase in coronary arteries.

Authors:  B Fisslthaler; R Popp; L Kiss; M Potente; D R Harder; I Fleming; R Busse
Journal:  Nature       Date:  1999-09-30       Impact factor: 49.962

8.  Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature.

Authors:  Anuradha Dhanasekaran; Rula Al-Saghir; Bernardo Lopez; Daling Zhu; David D Gutterman; Elizabeth R Jacobs; Meetha Medhora
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-14       Impact factor: 4.733

9.  Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel.

Authors:  Eric R Gross; Kasem Nithipatikom; Anna K Hsu; Jason N Peart; John R Falck; William B Campbell; Garrett J Gross
Journal:  J Mol Cell Cardiol       Date:  2004-12       Impact factor: 5.000

10.  Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.

Authors:  Yong-Fu Xiao; Qingen Ke; John M Seubert; J Alyce Bradbury; Joan Graves; Laura M Degraff; John R Falck; Kris Krausz; Harry V Gelboin; James P Morgan; Darryl C Zeldin
Journal:  Mol Pharmacol       Date:  2004-09-10       Impact factor: 4.436

View more
  50 in total

1.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

2.  Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Authors:  Eric A Evangelista; Rüdiger Kaspera; Nahush A Mokadam; J P Jones; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2013-09-10       Impact factor: 3.922

3.  Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Paulo Arnaldo; Ricardo Estevão Thompson; Márcia Quinhones Lopes; Philip Noel Suffys; Adalberto Rezende Santos
Journal:  Malays J Med Sci       Date:  2013-07

Review 4.  Eicosanoid signalling pathways in the heart.

Authors:  Christopher M Jenkins; Ari Cedars; Richard W Gross
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

5.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

6.  Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.

Authors:  Lauren N Carnevale; Andres S Arango; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2018-11-06       Impact factor: 3.162

7.  Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression.

Authors:  Zhe Shi; Wenjun Yang; Joyce A Goldstein; Shu-Yun Zhang
Journal:  Biochem Pharmacol       Date:  2014-06-21       Impact factor: 5.858

8.  Monocrotophos Induces the Expression of Xenobiotic Metabolizing Cytochrome P450s (CYP2C8 and CYP3A4) and Neurotoxicity in Human Brain Cells.

Authors:  Vinay Kumar Tripathi; Vivek Kumar; Ankita Pandey; Pankhi Vatsa; Anupam Dhasmana; Rajat Pratap Singh; Sri Hari Chandan Appikonda; Inho Hwang; Mohtashim Lohani
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

Review 9.  Roles of the epoxygenase CYP2J2 in the endothelium.

Authors:  Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-06       Impact factor: 3.072

10.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.